← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Cell-Type-Specific TFEB Modulation Combined with Trehalose f (TFEB) — 0.00 Alpha-theta entrainment therapy to enhance default mode netw (SST) — 0.00 GLUT1-Mediated Carrier-Conjugate Delivery Strategy (LDLR) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Stra (LDLR) — 0.00 LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy (LAMP2A) — 0.00 Closed-loop transcranial focused ultrasound with gamma entra (PVALB) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 Closed-loop transcranial focused ultrasound to restore hippo (SST) — 0.00 LAMP1 Overexpression to Enhance Lysosomal Capacity Independe (LAMP1) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 LDLR-Mediated Neurosteroid Precursor Delivery Strategy (LDLR) — 0.00 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.97 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Cortico-Striatal Synchrony Restoration via NMDA Modulation (GRIN2B) — 0.95 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece (MAPT) — 0.94 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.92 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.90 APOE-Dependent Autophagy Restoration (MTOR) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89
Add
|
× Exposure profile may matt
EIF2AK3; EIF2S1 · neurodegeneration · -
Composite 0.390
Price $0.49
Evidence For 0
Evidence Against 0
An extended-release or split-dose regimen could, in theory, improve overnight brain exposure and enable target engagement at lower total daily dose. However, this remains a PK/PD speculation without human dementia biomarker support, so it is better deferred until any clinical pharmacodynamic signal is established.
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Exposure profile may matter mo Mechanistic 0.480 Evidence 0.230 Novelty 0.500 Feasibility 0.440 Impact 0.390 Druggability 0.460 Safety 0.490 Competition 0.400 Data 0.290 Reproducible 0.250 KG Connect 0.500
Evidence Exposure profile may matter more than nominal daily dose, bu No evidence citations yet
Price History Overlay